Standard operating procedure Title: Paediatric investigation plan from re-start of procedure to PDCO opinion Status: PUBLIC

Document no.: SOP/H/3453

Lead author

Approver

Effective date: 1-DEC-2017

Name: Marketa Lisakova and

Name: Ralph Bax

Review date: 1-DEC-2020

Signature:

Signature:

Supersedes:

On File

On File

SOP/H/3453 (05-Oct-2015),

Andrea Davies

TW4549 Date: 1-DEC-2107

Date: 1-DEC-2017

TrackWise record no.: 4864

1. Purpose This SOP describes the handling of an application for a paediatric investigation plan from the receipt of the supplementary information from applicant in response to PDCO’s request for modification to adoption of PDCO opinion.

2. Scope This SOP applies to Paediatric Medicines Office in Product Development Scientific Support Department and Scientific Committees Secretariat in Committees and Inspections Department.

3. Responsibilities It is the responsibility of the Head of Paediatric Medicines Office to ensure that this procedure is adhered to. The responsibility for the execution of a particular part of this procedure is identified under section 9: Procedure.

4. Changes since last revision Minor revision and update following current EMA organigram

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.

5. Documents needed for this SOP Templates and deadline documents are located in DREAM: Cabinets/02b. Administration of Scientific Meeting/PDCO - Administration/1. Governance/10. Templates/ PME - Paediatric templates and timelines: •

PedRA procedural timelines and templates checklist



Appropriate PDCO opinion template



Timelines (EMA/690732/2015)



Summary report template generated by Business Intelligence through PedRA.

Eudralink message templates in PedRA (numbers are related to the message in the application): •

09 - Re-start of procedure



10 - Summary report for comments to Rapp and Peer



17 – Summary report Day 90 to applicant



18 - Draft opinion to Rapp and Peer



19 - Draft opinion to applicant



20 - Opinion to applicant

6. Related documents SOP/EMA/0040

Evaluation of conflicts of interests of experts for involvement in Agency activities

SOP/EMA/0101

Standard operating procedure for conducting checks for conflicts of interest when assigning medicinal products for human or veterinary use to a product / project team leader / member or project manager

SOP/H/3452

Paediatric investigation plan or a waiver from start of procedure to clock-stop or PDCO opinions

SOP/H/3454

Re-examination of PDCO opinions

SOP/H/3455

EMA decision-making process for decisions on PDCO opinions

WIN/H/3459

Paediatric core master files and numbering

Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 located at: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf Rules of procedure of the Paediatric Committee (PDCO) http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009 /10/WC500004749.pdf Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO) http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009 /10/WC500004754.pdf Procedural advice http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000608.js p&mid=WC0b01ac0580925b1b Standard operating procedure – PUBLIC, 1-Dec-2017 SOP/H/3453

Page 2/7

7. Definitions D61

Restart of procedure date

D90

Third discussion at PDCO meeting

D120

Fourth discussion and adoption of opinion at PDCO meeting

D-DS-PME

Paediatric Medicines Office in Product Development Scientific Support Department

DREAM

Document records electronic archive management

EudraLink

The European medicines regulatory network’s secure file-transfer system used for exchanging information for regulatory purposes

MMD

Managing meeting documents system

N-drive

Internal repository for PME

OEM

Oral explanation meeting

Paed AA

Paediatric administrative assistant (in D-DS-PME)

Paed Asst

Paediatric procedure assistant (in D-DS-PME)

Paed Asst (assigned)

Paediatric procedure assistant assigned to complete a specific task (assistant in D-DS-PME)

Paed Co

Paediatric coordinator (scientific officer in D-DS-PME)

Paed Co (assigned)

Paediatric coordinator assigned to complete a specific task (scientific officer in D-DS-PME)

Paed HoO

Head of Paediatric Medicines Office

PDCO

Paediatric Committee

PDCO Peer

PDCO peer reviewer

PDCO Rapp

PDCO rapporteur

PDCO Sec

Secretariat of the PDCO in Scientific Committees Secretariat in Committees and Inspections Department

PedRA

Paediatric Record Application (database)

PedRA template

Eudralink template available in Paediatric Record Application (database)

RfM

PDCO’s request for modifications to the initially submitted paediatric investigation plan

Standard operating procedure – PUBLIC, 1-Dec-2017 SOP/H/3453

Page 3/7

8. Process map(s)/ flow chart(s) From SOP/H/3452

1. Supplementary information is received; forms are uploaded. PDCO Rapp and PDCO Peer are listed for appointment. PedRA procedural timelines and, if needed, participants are updated.

8. D90 discussion: outcome is recorded in summary report and PedRA. Draft opinion is updated and sent to the PDCO Rapp and PDCO Peer for review, and to the applicant for administrative check. Comments are received and implemented, if applicable.

16. PDCO opinion and summary report are formatted for adoption by the PDCO.

17. The receipt (i.e. adoption) of the PDCO opinion is confirmed. Verification of document by Paed HoO is scheduled.

9. PedRA procedural timelines are updated. 2. PDCO Rapp and PDCO Peer are appointed at the PDCO plenary.

18. Review of completeness of all the procedural steps and readiness of document for transmission is confirmed.

10. Draft summary report (D90) is transmitted to the applicant. 3. Sufficiency of the received documents is confirmed.

4. Supplementary information is inserted into the draft summary report and draft PDCO opinion is created; drafts are forwarded to Paed Co. Applicant is informed of procedure restart (D61).

11. Procedure is included in the agenda for D120 adoption at the upcoming PDCO plenary. Oral explanation meeting is organised, if applicable.

12. Internal quality review of the draft PDCO opinion is performed. 5. Draft summary report and PDCO opinion are completed and sent for assessment to the PDCO Rapp and PDCO Peer. Commented drafts are received and forwarded to the Paed Asst. Comments are implemented into draft opinion. Additional experts are identified, if needed.

19. PDCO opinion with summary report is transmitted to the applicant. Document transmission receipt is recorded. PedRA procedural timelines are updated.

Continue to SOP/H/3454 or SOP/H/ 3455

13. Comments from the internal quality review are implemented into the draft PDCO opinion. Comments received from the PDCO members are included into the draft summary report.

6. PDCO Rapp’s and PDCO Peer’s assessments are included in the draft summary report. 14. D120 discussion: outcome is recorded in summary report and PedRA. Summary report and PDCO opinion are finalised. 7. Procedure is included in the agenda for D90 discussion at the upcoming PDCO plenary.

15. PedRA procedural timelines are updated.

Standard operating procedure – PUBLIC, 1-Dec-2017 SOP/H/3453

Page 4/7

9. Procedure Notes: •

Declarations of interest are checked and evaluated for all staff before involvement according to SOP/EMA/0101 and SOP/EMA/0040 listed under “Related documents”.



All messages containing confidential information must be sent via EudraLink, using the appropriate PedRA template if available.



All procedural timelines and application guidance are published on the EMA website.



All meeting documents are linked to appropriate DREAM meeting folders by Paed Asst prior meeting and regularly tabled in MMD by PDCO Sec, before during and after PDCO plenary. Step

Action

Responsibility

Continue from SOP/H/3452 Clock-stop (post D60) 1.



Receive supplementary information (answers to PDCO RfM) from

Paed AA

applicant; upload form(s) to PedRA. •

List PDCO Rapp and PDCO Peer for appointment by the PDCO.



Update procedural timelines and, if needed, the participants in PedRA.

Note: If available, participants should be the same as before clockstop. 2.

Ensure the appointment of PDCO Rapp and PDCO Peer at the

PDCO Sec

upcoming PDCO plenary. 3.

Confirm the sufficiency of the received documents to Paed Asst.

Paed Co

Re-start of procedure 4.



Insert the supplementary information into the draft summary

Paed Asst

report and create draft PDCO opinion; forward both to Paed Co. •

Inform the applicant of the re-start of procedure at D61.

Pre and post D90 5.



Complete the draft summary report and PDCO opinion and send

Paed Co

both for assessment to the PDCO Rapp and PDCO Peer. •

Receive the commented draft summary report and PDCO opinion from the PDCO Rapp and PDCO Peer and forward to the Paed Asst if not in copy.



Implement comments into draft PDCO opinion.



Identify the need and, if agreed by PDCO, organise the involvement of additional experts.

Standard operating procedure – PUBLIC, 1-Dec-2017 SOP/H/3453

Page 5/7

Step 6.

Action

Responsibility

Include the PDCO Rapp and PDCO Peer assessment into the summary

Paed Asst

report. 7.

Include the procedure in the agenda for D90 discussion at the

PDCO Sec

upcoming PDCO plenary. 8.



Participate in the D90 discussion.



Record the minutes of the D90 discussion in PedRA and in the

Paed Co

draft summary report. 1 •

Update the draft PDCO opinion accordingly and send it to the PDCO Rapp and PDCO Peer for a review, and to the applicant for administrative check.



Receive and implement comments into draft PDCO opinion, if applicable.

9.

Update procedural timelines in PedRA.

Paed AA

10.

Transmit the draft summary report (D90) to the applicant for

Paed Asst

information or for clarification if requested. Pre and post D120 11.



Include the procedure in the agenda for adoption at the upcoming

PDCO Sec

PDCO plenary. •

If applicable, schedule and invite the applicant for an oral explanation meeting.

12.

Perform an internal quality review of the draft PDCO opinion.1

Paed Co (assigned)

13.



Implement comments from the quality review into the draft PDCO

Paed Co

opinion as appropriate. •

Include comments received from the PDCO members into the draft summary report as appropriate.

14.



Participate in the D120 discussion.



Record the minutes of the D120 discussion in PedRA and in

Paed Co

summary report. •

Finalise the content of the summary report and the PDCO opinion.1

15.

Update procedural timelines in PedRA.

Paed AA

16.

Format the PDCO opinion and summary report for adoption by the

Paed Asst

PDCO. 17.



Confirm the receipt (i.e. adoption) of the PDCO opinion1.



Schedule the verification of document by Paed HoO.

Standard operating procedure – PUBLIC, 1-Dec-2017 SOP/H/3453

Paed Asst (assigned)

Page 6/7

Step 18.

Action

Responsibility

Review the completeness of all the procedural steps and confirm the

Paed HoO

readiness of the document for transmission1. Note: if required, obtain immediately further clarification from Paed Co. 19.



Transmit electronically the PDCO opinion merged with the

Paed Asst

summary report to the applicant within ten days of receipt from the PDCO (i.e. adoption date). •

Obtain and save the record of document transmission and receipt (accessed) by the applicant.



Update procedural timelines in PedRA.

Continue to SOP/H/3454 or SOP/H/3455.

10. Records Electronic documents are saved in the appropriately labelled folders in DREAM and on N:\ drive. 1

Task completion is confirmed by labelling the document version in DREAM appropriately.

Standard operating procedure – PUBLIC, 1-Dec-2017 SOP/H/3453

Page 7/7

Standard operating procedure - European Medicines Agency - Europa ...

Standard operating procedure. Title: Paediatric investigation plan from re-start of procedure (after clock-stop) to PDCO opinion. Status: PUBLIC. Document no.: SOP/H/3453 ... Committee Support Department in Procedure Management and Committees Support Division. 3. .... labelled folders in DREAM and on N:\ drive.

132KB Sizes 7 Downloads 206 Views

Recommend Documents

Agenda - European Medicines Agency - Europa EU
Jul 7, 2017 - COMMUNITY MARKETING AUTHORISATIONS AND EXTENSIONS. 2.1. Opinions ... Quality. Rapp: E. Werner .... solutions table with EMA and CVMP responses to the recommendations made by the FishMed Plus. Coalition ...

May 2016 - European Medicines Agency - Europa EU
Jun 22, 2016 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

Eleclazine - European Medicines Agency - Europa EU
Feb 9, 2017 - Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply).

July 2017 - European Medicines Agency - Europa EU
Jul 5, 2017 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

July 2016 - European Medicines Agency - Europa EU
Jul 4, 2016 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

SME Office - European Medicines Agency - Europa EU
maximises the chances of a successful marketing authorisation. ... marketing authorisation. • inclusion in the public SME ... E-mail [email protected]. Website ...

drospirenone / ethinylestradiol - European Medicines Agency - Europa ...
May 5, 2017 - Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5525. Send a question via our ... List of nationally authorised medicinal products.

Agenda - European Medicines Agency - Europa EU
Jun 19, 2017 - and may also vary during the course of the review. ...... ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus ..... adjunctive administration of brivaracetam, Treatment of paediatric patients with partial.

Action plan - European Medicines Agency - Europa EU
5 days ago - Guidelines should include more details on the principles of good information design in which content and layout are ... relevance and importance of the QRD template is also acknowledged in this respect as it is the main tool .... databas

Agenda - European Medicines Agency - Europa EU
Jun 15, 2016 - Agenda - EMA Human Scientific Committees' Working. Parties with Healthcare Professionals' Organisations. (HCPWP) meeting. 15 June 2016, 08:45hrs to 10:30hrs – meeting room: 3E. Chairs: I. Moulon (EMA) and Gonzalo Calvo (HCPWP). 15 Ju

Agenda - European Medicines Agency - Europa EU
Jun 26, 2018 - oxadiazole-3-carboximidamide - EMEA-002072-PIP01-16-M01 . ..... Human alpha-galactosidase A - Orphan - EMEA-001828-PIP01-15-M01 .

Agenda - European Medicines Agency - Europa EU
Jul 16, 2018 - Cladribine, EMA/OD/087/17 Recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8. 2.2.6. - EMA/OD/098/18. Treatment of ...

SPOR - European Medicines Agency - Europa EU
Feb 7, 2017 - Add an existing Tag to a specific Term . ...... This service creates an email body (text/html) of a user's notification data, a notification is based on.

ATMP - European Medicines Agency - Europa EU
Nov 24, 2017 - E8. 09/08/2017. 10/08/2017. 24/08/2017 17/08/2017 22/08/2017. 24/08/2017. 30/08/2017. 01/09/2017. 04/09/2017. 08/09/2017. 14/09/2017.

Agenda - European Medicines Agency - Europa EU
Feb 9, 2018 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union ... product information. For information: Summary of opinion. 2.2. Oral explanations and list of outstanding issues. •. Product

Agenda - European Medicines Agency - Europa EU
Oct 23, 2017 - Page 2/61. Table of contents. 1. Introduction. 11. 1.1. Welcome and declarations of interest of members, alternates and experts .......... 11. 1.2. Agenda of the meeting on 23-26 October 2017 . ...... different database to study the ri

Evofosfamide - European Medicines Agency - Europa EU
Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply). (possible) lack of ...

Agenda - European Medicines Agency - Europa EU
17 Jan 2018 - Expert meeting on adeno-associated viral vectors, 06 September 2017, EMA, London. CAT: Martina Schüßler-Lenz. Scope: report of the meeting that took place on 6 September 2017. Action: for adoption. 7.6.3. Environmental assessment of g

minoxidil - European Medicines Agency - Europa EU
Jun 14, 2018 - Page 2/26. Product Name (in authorisation country). MRP/DCP Authorisation number. National Authorisation. Number. MAH of product in the.

Influenza vaccine - European Medicines Agency - Europa EU
Oct 26, 2017 - Injektionssuspension in einer Fertigspritze. Influenza-Impfstoff. (Spaltimpfstoff, inaktiviert, in Zellkulturen hergestellt) not available. BE393556. NANOTHERAPEUTICS. BOHUMIL, S.R.O.. BE. Preflucel injektionsvätska, suspension i för

latanoprost - European Medicines Agency - Europa EU
May 13, 2016 - Send a question via our website www.ema.europa.eu/contact. © European ... Product Name (in authorisation ..... Xaloptic Free. NL/H/3193/001.

Cyproterone/ethinylestradiol - European Medicines Agency - Europa EU
March 2016 a joint database drug utilisation final study report to the European .... With regards to prescription of CPA/EE for contraceptive management, ...

ganciclovir - European Medicines Agency - Europa EU
Feb 9, 2017 - Send a question via our website www.ema.europa.eu/contact. © European ... Product Name (in authorisation ... not available. 20010180.

July 2016 - European Medicines Agency - Europa EU
For a list of RSS readers please refer to our RSS guide and follow the instructions ..... PCWP and HCPWP joint meeting: Workshop on social media - Sep 2016.